Article Text

other Versions

Inhibition of TNF and IL-17 production by leflunomide involves the JAK/STAT pathway
  1. Isidoro González-Alvaro ({at}
  1. Hospital Universitario La Princesa, Spain
    1. Ana M Ortiz García (lanult{at}
    1. Hospital de la Princesa, Spain
      1. Carmen Domínguez-Jiménez (mcarmendj{at}
      1. Hospital de la Princesa, Spain
        1. Ana Aragón-Bodi (ana_aragon_bodi{at}
        1. Hospital de la Princesa, Spain
          1. Belen Díaz-Sánchez (belen.d.s{at}
          1. Hospital de la Princesa, Spain
            1. Francisco Sánchez-Madrid (fsanchez.hlpr{at}
            1. Hospital de la Princesa, Spain


              Objective: To study the effects of different disease modifying anti-rheumatic drugs (DMARDs) on different events mediated by IL-15-activated lymphocytes.

              Methods: Peripheral blood lymphocytes (PBL) were isolated from healthy donors and activated with IL-15 after exposure to different DMARDs: leflunomide, cyclosporin A, methotrexate, mycophenolic acid, FK-506, sulphasalazine and sodium aurothiomalate. The expression of different surface molecules on the PBL was then determined by flow-cytometry. Cells were also co-cultured with the monocytic cell line THP-1 and the TNF concentration in the supernatant was measured after 24 h using an immunoenzyme assay. The effect of the aforementioned drugs on IL-17 production by IL-15-activated PBL was also studied.

              Results: Treatment of PBL with leflunomide, cyclosporin A and FK-506 inhibited the IL-15-induced expression of both CD54 and CD69 by PBL, as well as TNF production in co-cultures of activated-PBL and THP-1 cells. The down-regulation of CD54 and CD69 in PBL was correlated with the inhibition of TNF production. Likewise, leflunomide, cyclosporin A and FK-506 all inhibited IL-17 production in IL-15-activated PBL. Interestingly, the effect of leflunomide was not reverted by the presence of uridine in the medium. In addition, leflunomide inhibited the phosphorylation of STAT6 in vitro.

              Conclusion: Inhibition of the JAK/STAT pathway may represent an additional effect of leflunomide in chronic polyarthritis since it impairs certain events that control proinflammatory TNF and IL-17 cytokine production.

              Statistics from

              Request permissions

              If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.